Ownership of Human Tissues and Cells: New Developments in Biotechnology
The Minerva Group, Inc., 2002 - 180 sider
In this special report, the Office of Technology Assessment of the United States Congress analyzes the economic, legal and ethical rights of the human sources of tissues and cells and also those of the physicians or researchers who obtain and develop these biological materials. The study describes the potential of these rapidly moving technologies (tissue and cell culture, cell fusion to produce monoclonal antibodies, and recombinant DNA) for manipulating human tissues and cells to yield commercially valuable products. The report includes a range of options for congressional action related to commercialization of human biological materials, regulation of research with human subjects, and disclosure of physicians commercial interest in patient treatment.
Hva folk mener - Skriv en omtale
Vi har ikke funnet noen omtaler på noen av de vanlige stedene.
Questions for the Future coco co co vyverer er er A w
Table No Page
action activities addition antibodies application approved benefits biotechnology blood body called cell culture cell line claim cloned commercial gain common companies concerning consider continue costs courts Department determine developed disclosure donations established ethical example existing factor Federal funded gene genetic growth Health human biological materials human cells human tissues hybridoma important individual industry informed consent institution interest inventions involving isolated issues limited living ment molecule moral nature nonprofit obtained organs original participation particular patient payment person physician possible potential principle probably procedures profits protection protein reason recombinant regarding regulations relationship removed requirements research subjects respect response result risks sample setting sources specific specimens substance tion tissues and cells tort transplantation treatment tumor types University